GlySure Presents Successful Medical ICU Study Results at ESICM
Data reveals truly continuous glucose sensor delivers clinically relevant accuracy throughout length of stay in critically ill patients
OXFORD, England, September 29, 2014 /PRNewswire/ --
GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, announced that Dr. Gopal Palepu is presenting the results of his Medical Intensive Care Unit (MICU) study at the European Society of Intensive Care Medicine (ESICM) 27th Annual Congress, September 27 - October 1, 2014 in Barcelona.
The investigators had previously trialled GlySure's technology within a cardiac surgery patient population. In this current study, entitled "Application of a Continuous Intravascular Blood Glucose Sensor to a MICU patient population," they extended their investigations to include potentially more challenging MICU patients, where the stimulated immune system, compromised organ function and poor perfusion of the critically ill can challenge the ability to generate accurate continuous blood glucose readings.
The researchers compared the accuracy of the GlySure system versus intermittent blood glucose measurement in 20 patients admitted in 10 MICUs across six hospitals from the time of admission to the time of discharge. The patients were between 26 and 85 years of age with diverse conditions, including pneumonia, sepsis, acute gastroenteritis, hemoperitoneum, chronic kidney disease, CAD, cerebral vascular accident, meningitis, acute pancreatitis and polytrauma.
The data revealed that GlySure's truly continuous intravascular sensor generated clinically relevant accuracy (MARD 9.5% with 88.2% in the A zone and 100% in the A+B zone of the Consensus Error Grid) that could optimise glucose management throughout the length of stay in critically ill patients.
"This is a significant step in demonstrating the ability to accurately and continuously monitor blood glucose across all ICU patients," said Principal Investigator Dr. Gopal Palepu. "An easy-to-use, accurate CBGM system will enable us to provide more effective glucose control on our critically ill patients."
About GlySure:
GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com
Company Contact: Chris Jones, CEO, GlySure. Tel: +44-(0)1235-462-870. [email protected]
Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127. [email protected]
SOURCE GlySure Limited
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article